Clinical Outcomes of Patients with Metastatic Breast Cancer Treated with Hypo-Fractionated Liver Radiotherapy.
SABR
SBRT
ablative radiotherapy
breast cancer
liver metastasis
metastases
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 May 2023
19 May 2023
Historique:
received:
13
04
2023
revised:
11
05
2023
accepted:
13
05
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
To retrospectively review the clinical outcomes of patients with metastatic breast cancer (MBCa) following liver directed ablative intent radiotherapy (RT). Demographics, disease and treatment characteristics of patients with MBCa who received liver metastasis (LM) directed ablative RT between 2004-2020 were analysed. The primary outcome was local control (LC), secondary outcomes included overall survival (OS) and progression-free survival (PFS) analyzed by univariate (UVA) and multi-variable analysis (MVA). Thirty MBCa patients with 50 LM treated with 5-10 fraction RT were identified. Median follow-up was 14.6 (range 0.9-156.2) months. Class of metastatic disease was described as induced (12 patients, 40%), repeat (15 patients, 50%) and de novo (three patients, 10%). Median size of treated LM was 3.1 cm (range 1-8.8 cm) and median biologically effective dose delivered was 122 (Q1-Q3; 98-174) Gy Hypo-fractionated ablative liver RT in patients with MBCa provides safe, tolerable treatment with excellent LC.
Identifiants
pubmed: 37345175
pii: cancers15102839
doi: 10.3390/cancers15102839
pmc: PMC10216793
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Radiol. 2013 Mar;86(1023):20120601
pubmed: 23392193
Radiother Oncol. 2017 May;123(2):227-233
pubmed: 28274491
Strahlenther Onkol. 2020 Sep;196(9):813-820
pubmed: 32399637
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):587-595
pubmed: 35738308
Strahlenther Onkol. 2019 Dec;195(12):1113-1115
pubmed: 31637448
Acta Oncol. 2006;45(7):856-64
pubmed: 16982550
Clin Oncol (R Coll Radiol). 2019 Dec;31(12):824-833
pubmed: 31182289
Mol Cancer Ther. 2003 Nov;2(11):1113-20
pubmed: 14617784
Radiother Oncol. 2020 Jul;148:157-166
pubmed: 32388150
BMC Cancer. 2012 Sep 28;12:435
pubmed: 23020297
Clin Exp Metastasis. 2021 Jun;38(3):263-277
pubmed: 33675501
Radiother Oncol. 2021 Aug;161:159-165
pubmed: 34119585
Cancer Discov. 2022 Jan;12(1):8-9
pubmed: 34789539
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
Radiat Oncol J. 2015 Dec;33(4):301-9
pubmed: 26756030
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
BMC Cancer. 2021 Mar 6;21(1):238
pubmed: 33676449
JAMA Netw Open. 2020 Nov 2;3(11):e2026312
pubmed: 33196810
Anticancer Res. 2017 May;37(5):2709-2713
pubmed: 28476849
Breast Cancer Res Treat. 2009 Jun;115(3):601-8
pubmed: 18719992
BMC Cancer. 2019 Feb 26;19(1):173
pubmed: 30808323
Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):163-169
pubmed: 28490988
Med Oncol. 2021 Jan 4;38(1):3
pubmed: 33394200
Swiss Med Wkly. 2021 Feb 15;151:w20390
pubmed: 33631027
Anticancer Res. 2020 Oct;40(10):5895-5899
pubmed: 32988920
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Breast. 2018 Dec;42:150-156
pubmed: 30296648
Radiat Oncol. 2018 Feb 13;13(1):26
pubmed: 29439707
J Clin Oncol. 2009 Apr 1;27(10):1585-91
pubmed: 19255313
Radiother Oncol. 2020 Jan;142:236-245
pubmed: 31543287
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301